September 20, 2017
Via: The Medical NewsA phase 1 clinical trial published in the British Journal of Clinical Pharmacology found that radavirsen — an antisense oligomer that inhibits the production of certain influenza proteins — is safe and well-tolerated in healthy individuals. Additional studies on radavirsen’s […]